Last updated 8 days ago
A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors
124 patients around the world
Available in United States, Brazil
Pfizer
1Research sites
124Patients around the world
This study is for people with
Skin cancer
Melanoma
Brain Tumor
Glioma
Thyroid cáncer
Lung cancer
Non-small cell lung carcinoma
Colorectal cancer
Brain tumor
Primary brain tumor
Requirements for the patient
From 16 Years
All Gender
Medical requirements
- Diagnosis of advanced/metastatic solid tumor including primary brain tumor for monotherapy phase 1a dose escalation.Disease progressed during/following last prior treatment and no satisfactory alternative treatment options for monotherapy phase 1a dose escalation.For Substudy B, histological or cytological diagnosis of advanced/metastatic melanoma.For Substudy C, unresectable or adv/metastatic solid tumor progressed on, or with demonstrated intolerance to SOC, excluding melanoma.For Substudy B and C, measurable disease by RECIST version 1.1.For Substudy B, evidence of a BRAF V600 mutation or BRAF Class II/III alteration in tumor tissue and/or blood.For Substudy C, evidence of a BRAF founder alteration (non-V600 Class II/III BRAF alteration).
- Brain metastasis larger than 4 cm.History or current evidence of retinal vein occlusion (RVO) or concurrent neuromuscular disorder associated with elevated creatine kinase (CK).
Sites
Ceon+ Centro de Oncologia
SponsorPfizer
Study typeInterventional
Conditions
MelanomaGliomaThyroid cáncerNon-small cell lung carcinomaColorectal cancerPrimary brain tumor
Requirements
From 16 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT05538130
